HIV-1-RNA and Total HIV-1-DNA Loads in the Genital Compartment in Men Receiving Dolutegravir- versus Darunavir-Based Combined ART (cART) Regimens during Primary HIV Infection - Sorbonne Université Access content directly
Journal Articles Journal of Antimicrobial Chemotherapy Year : 2022

HIV-1-RNA and Total HIV-1-DNA Loads in the Genital Compartment in Men Receiving Dolutegravir- versus Darunavir-Based Combined ART (cART) Regimens during Primary HIV Infection

Abstract

Abstract Background Dolutegravir is a widespread integrase strand-transfer inhibitor (INSTI) recommended for treatment of primary HIV infection (PHI). PHI is a high-risk stage for sexual transmission because of the high viral load in semen. Yet dolutegravir concentrations in semen are lower than in blood during chronic treatment. Objectives To compare the kinetics of HIV-RNA and total HIV-DNA in the genital compartment in subjects receiving either tenofovir/emtricitabine/dolutegravir or tenofovir/emtricitabine/darunavir/cobicistat as a first-line combined ART (cART) at the time of PHI. Patients and methods Eighteen subjects receiving tenofovir/emtricitabine/dolutegravir and 19 receiving tenofovir/emtricitabine/darunavir/cobicistat enrolled in the ANRS169 OPTIPRIM-2 trial participated in the genital substudy. Results Between week (W) 0 and W2 HIV-RNA in seminal plasma (SP) decreased by 1\,log10 copies/mL. Undetectable SP HIV-RNA was achieved in similar proportions between the two regimens at each timepoint. Overall, eight patients still presented detectable HIV-RNA or HIV-DNA in semen at W48; 15.4% and 28.6% presented detectable HIV-RNA and 9.1% and 14.3% presented detectable HIV-DNA in dolutegravir- and darunavir-based cART groups, respectively, with no significant difference. Conclusions For the first time, to the best of our knowledge, we showed that a dolutegravir-based regimen initiated as soon as PHI reduces HIV-RNA and HIV-DNA with no difference compared with a control group receiving a darunavir-based regimen. Although the viral purge in semen seems longer after treatment in PHI than CHI, due to high viral loads, early dolutegravir-based treatment initiation permits a major decay of both viral particles and infected cells in semen, efficiently reducing the high risk of transmission during PHI.

Dates and versions

hal-03793489 , version 1 (01-10-2022)

Identifiers

Cite

Alice-Andrée Mariaggi, Rebecca Bauer, Caroline Charre, Elise Gardiennet, Vincent Meiffrédy, et al.. HIV-1-RNA and Total HIV-1-DNA Loads in the Genital Compartment in Men Receiving Dolutegravir- versus Darunavir-Based Combined ART (cART) Regimens during Primary HIV Infection. Journal of Antimicrobial Chemotherapy, 2022, 77 (3), pp.735--739. ⟨10.1093/jac/dkab427⟩. ⟨hal-03793489⟩
17 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More